Loading stock data…
NMRA
$2.31-0.13 (-5.33%)
After Hours$2.34+0.03 (+1.20%)· Last close May 4
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Neumora Therapeutics, Inc. in the Healthcare sector is trading at $2.39. The stock is currently 35% below its 52-week high of $3.65, remaining 9.1% above its 200-day moving average. Technical signals show overbought RSI of 70 and bullish MACD crossover, explaining why NMRA maintains its current momentum and trend strength. The Whystock Score of 20/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Overbought levels (RSI 70) — risk of consolidation or pullback
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$2.31
Potential Upside
5%
Whystock Fair Value$2.43
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus8 analysts
Buy
Mean target$8.91+285.6%
Range$3.00 – $18.00
Fundamentals
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$422.01M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
3.12
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-242.69%
Volume
Today's trading volume
1.23M
Recent News
Neumora Therapeutics (NMRA) Is Among the Best Penny Stocks Set to Explode
Neumora Therapeutics, Inc. (NASDAQ:NMRA) is featured in our list of the best penny stocks set to explode. As of April 8, 2026, analyst sentiment toward Neumora Therapeutics, Inc. (NASDAQ:NMRA) remains bullish, with 78% of analysts assigning a “Buy” rating to the stock. The consensus price target of $8 implies a potential upside of 275.59%. Reinforcing […]
Neumora Therapeutics, Inc. Common Stock Q4 2025 Earnings Call Summary
Moby summary of Neumora Therapeutics, Inc. Common Stock's Q4 2025 earnings call
Neumora Therapeutics Inc (NMRA) Q4 2025 Earnings Call Highlights: Strong Financial Position ...
Neumora Therapeutics Inc (NMRA) showcases promising clinical developments and a robust cash runway, despite facing setbacks in toxicology studies.
Neumora Therapeutics Q4 Earnings Call Highlights
Neumora Therapeutics (NASDAQ:NMRA) outlined clinical and pipeline updates alongside its fourth-quarter and full-year 2025 financial results, highlighting multiple anticipated data catalysts in 2026 and providing additional detail on several preclinical and clinical programs. Management highlights “
Neumora Therapeutics (NMRA) Positioned to Capitalize on Blockbuster Opportunity
Neumora Therapeutics Inc. (NASDAQ:NMRA) is one of the 11 most popular AI penny stocks to buy now. On February 17, Myles Minter from William Blair upgraded his rating on Neumora Therapeutics Inc. (NASDAQ:NMRA) from Market Perform to Outperform. The analyst also shared a net present value figure of $7.62 per share for the stock’s valuation. […]